Flatlander schreef op 30 januari 2020 00:41:
Your point about the business model is well taken. Up until this point we have primarily been discussing console sales and proprietary cartridge content. The business model will change when we have to start figuring partner content cartridges (OncoType Dx, Septicyte, etc.) where BCART gets reimbursed for its manufacturing costs and receives a royalty based on the content providers sales, profits etc. The fact of the matter is we do not know the specific terms for any of these partnerships. One thing that usually occurs, is that the early partners get better terms than the later ones once Idylla becomes better established.
My chief concern in these types of partnerships is that the development time seems to be eclipsing my previous estimate of 2 years, where it now appears to be 3 years or more from the time of the announcement of a partnership until the time that EU marking is achieved. Since the systems may be deployed for decades, this is probably tolerable. However, length development time could become an impediment to new partnerships. I realize a lot of technology is necessary for each assay. However, a major focus must remain expediting the R&D product cycle process.
Agree with the first part of your argument, not necessarily with the second. OncoType Dx got postponed because of the GH ES merger. Nothing to do with the development process. Septicyte on the other hand may well be on track because Immunexpress announced their funding round for 510k approval already back in October, so less then a full two years after the announcement of the partnership.